Dioseve, a Tokyo-based biotech startup working in the ART (assisted reproductive technology) space has raised around $3M (400M JPY) to re-engineer oocyte development. The round was led by ANRI with participation from Coral Capital. The company’s technology, DIO (Directly Induced Oocyte), is capable of producing a larger yield of fertilizable egg cells at minimal cost in a fraction of the time. Dioseve’s…
Nanopath, a molecular diagnostics company enabling high-quality molecular testing in minutes, has raised $10M in Series A funding, co-led by Norwest Venture Partners and the Medtech Convergence Fund. Other participants in the round include Gingerbread Capital and Green D Ventures. The new funds will support development and commercialization of Nanopath’s biosensing platform that aims to transform how women’s pelvic and gynecologic infections are diagnosed. Amogha…
Global women’s health pharma company Organon has entered into an agreement with Shanghai Henlius Biotech, whereby Organon will license commercialization rights for biosimilar candidates referencing Perjeta (pertuzumab, HLX11) and Prolia/Xgeva (denosumab, HLX14). Organon will acquire exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan. Pertuzumab is used for the treatment of certain patients with HER2+ breast cancer in combinations with…
Women’s health biotech company Oviva Therapeutics has announced an in-licensing agreement with Massachusetts General Hospital (MGH) of a family of patents, as well as $11.5M in seed funding, to develop first-in-class therapeutics to improve healthspan, the period of life spent in good health, in women. Oviva Therapeutics addresses the vast unmet need in women’s health by expanding funding, research, and clinical development of treatments…
Mirvie‘s proprietary RNA platform combines revolutionary analysis of tens of thousands of RNA messages from the baby, the placenta and the mom, with machine learning. The platform opens a new window into pregnancy health for expecting parents to act and their doctors to intervene before unexpected complications become a crisis. It can predict preeclampsia and preterm birth months before they happen by…
We last spoke about Celmatix in January, when the company announced that a novel PCOS target identified as part of its five-year, multi-target alliance with Evotec has progressed into hit-identification. Now the company is back with more promising news and this time it’s about premature menopause. According to a release Celmatix has identified of a novel AMHR2 agonist compound that has demonstrated…
Biotech firm Renegade.bio and Metabolomic Diagnostics are teaming up to develop a novel pre-eclampsia risk screening test, with plans to launch in the U.S. in late 2022. The test will be jointly developed specifically for the U.S. population, improving upon available assessments by creating a personalized risk profile for individuals. It measures a panel of biomarkers in blood that serves as early…
Amyris, a synthetic biotech company breaking into Clean Health & Beauty, is getting serious about the menopause market with the acquisition on Menolabs, who have developed line of all natural, proprietary supplements focused on treating perimenopause and menopause symptoms as well as a menopause health tracking app, and a community forum. Amyris previously shared its intention of launching a new consumer brand…
